This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Transcranial magnetic stimulation measurements could prove useful for prognosis of epilepsy patients

Transcranial magnetic stimulation measurements could provide useful for prognosis of epilepsy patients
Correlation between greater repeat number (GRN) and long-interval intracortical inhibition (LICI) (A), mean short-interval intracortical inhibition (mSICI) (B), and combined intracortical inhibition (cICI) (C). Data are shown for individuals with biallelic repeat expansions. Credit: Epilepsia (2022). DOI: 10.1111/epi.17466

In patients with progressive myoclonic epilepsy type 1 (EPM1), abnormality of intracortical inhibition measured by transcranial magnetic stimulation (TMS) is associated with the magnitude of the genetic change, a new study shows. According to the researchers, TMS could prove useful in assessing patient prognosis.

The study was undertaken at Kuopio University Hospital, the University of Eastern Finland, Chalfont Center for Epilepsy in London and University College London, and the results were published in Epilepsia.

EPM1 (also known as Unverricht-Lundborg disease) is a rare, severe epilepsy. It is caused by changes in both copies of an individual's CSTB gene. In most people with EPM1, the change in both copies is a repeat expansion (homozygous repeat expansion variant). The mechanisms by which loss of function of the CSTB protein leads to epilepsy and other manifestations of EPM1 remain incompletely understood. Previous research suggests that abnormal function of inhibitory networks of the surface of the brain, mediated by (GABA), may be involved.

Unfortunately, there are no disease-modifying treatments for EPM1. The condition is progressive, and most ultimately lose the ability to mobilize without walking aids and have difficulties with many activities of daily living. However, there is significant variability in the course of the disease from individual to individual. There is some evidence suggesting that among patients with EPM1, the longer expansion variant may be associated more severe disease.

Paired-pulse TMS is a non-invasive test for studying GABA-mediated inhibitory networks of the surface of the brain. Therefore, it might be a useful tool for gaining more insight into EPM1. Indeed, earlier studies have shown that people with EPM1 had impaired short-interval intracortical inhibition (SICI).

The present study examined the association between intracortical inhibition and clinical and genetic features in a group of individuals with EPM1. Nineteen people with EPM1 and seven healthy control participants completed the study. Compared to controls, patients demonstrated significantly less SICI. On a group level, no difference was seen between patients and controls with respect to long interval intracortical inhibition (LICI).

A combination of the two measures of intracortical inhibition was robust in discriminating patients and controls. In patients with EPM1 due to homozygote repeat expansions, the number of repeats in the more affected allele showed significant correlation with both measures of intracortical inhibition, with individuals with higher repeat number showing more impairment.

The results strengthen the finding of deranged GABAergic inhibition in EPM1. Intracortical as measured by may have use as a marker of GABAergic impairment in future treatment trials in EPM1.

More information: Katri Silvennoinen et al, Short‐ and long‐interval intracortical inhibition in EPM1 is related to genotype, Epilepsia (2022). DOI: 10.1111/epi.17466

Journal information: Epilepsia

Citation: Transcranial magnetic stimulation measurements could prove useful for prognosis of epilepsy patients (2023, January 11) retrieved 25 March 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Unverricht-Lundborg disease is more common in Finland than elsewhere in the world


Feedback to editors